Management uses these measures to establish operational goals and review operational performance and believes that these measures may assist investors in analyzing the underlying trends in the company's business over time. The company will also discuss certain non-GAAP financial measures during the call. Management encourages you to review the company's past and future filings with the SEC, including without limitation, the company's Forms 10-Q and 10-K, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. This conference call is also being broadcast live over the Internet at the Investors section of the company's website at and the webcast replay of the call will be available at the same site approximately 1 hour after the end of today's call.īefore we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margins for fiscal year 2024 as well as trends that may continue. (Operator Instructions) The news release detailing AngioDynamics fourth quarter and fiscal year 2023 results crossed the wire earlier this morning and is available on the company's website.
Good morning, and welcome to the AngioDynamics Fourth Quarter and Fiscal Year 2023 Earnings Call.
William John Plovanic Analyst Canaccord Genuity Corp., Research Division Presentation Matthew Ian Mishan VP & Senior Equity Research Analyst KeyBanc Capital Markets Inc., Research Division
0 kommentar(er)
